Download presentation
Presentation is loading. Please wait.
1
Bloodborne Pathogens Standard, 29 CFR 1910.1030 NJ Department of Health and Senior Services PEOSH Program (609) 984-1863
2
Bloodborne Pathogens Standard 29 CFR 1910.1030, Occupational Exposure to Bloodborne Pathogens Published December 1991 Effective March 1992 (Private Employers) Adopted Under NJ PEOSHA July 1993 Scope ALL with occupational exposure to blood and other potentially infectious material (OPIM)
3
Routes of Exposure Exposure incident means a specific contact with blood or OPIM through: Cuts, Cracks or Abrasions in the Skin Splashing or Spraying of Blood or OPIM in the Eyes, Mouth, or Nose Puncture Wounds from Contaminated Sharps (needles, broken glass, or other medical devices)
4
Methods of Compliance Universal Precautions Engineering and Work Practice Controls Personal protective equipment Housekeeping
5
Universal Precautions An infection control concept that requires all blood and OPIM to be handled as if it were infected with bloodborne pathogens.
6
Work Practice Controls Wash Hands Immediately After Glove Removal Decontaminate Equipment Before Servicing Use labeled or Color-Coded Bio Hazard Containers Do Not Eat, Drink, Smoke, etc. in Work Areas Do Not Recap, Bend or Break Needles
7
Exposure Control Plan Written plan to eliminate or minimize exposures to bloodborne pathogens List job classifications at risk (exposure determination) ID procedures in which occupational exposure can occur Explain how the Standard will be complied with How employees will be protected How employees will be trained Person to contact if an exposure occurs
8
Hepatitis B Vaccination Made available to employees after training and within 10 working days of initial assignment A declination form must be signed if vaccination is refused by the employee Post-exposure follow-up is required to be provided to an employee after an exposure incident
9
Hepatitis B Vaccination Current Recommendations For HCP who are in contact with patients and/or blood and continues to be at risk for percutaneous exposure, they must be: tested 1-2 months after completion of the vaccination for antibody titer. Source: CDC, MMWR, June 29, 2001/Vol.50/No. RR-11
10
Hepatitis B Vaccine 3 – Dose Series How long the protective effect in healthy adults last is unknown at present; currently no booster is required.
11
Bloodborne Pathogens Standard, 29 CFR 1910.1030 Review of Facility-Specific Exposure Control Plan Additional Question and Answer Period
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.